Please login to the form below
chronic diseases
This page shows the latest chronic diseases news and features for those working in and with pharma, biotech and healthcare.
Anavex’s CNS drug slows progression of motor and non-motor symptoms in Parkinson’s disease
Independent research also strengthens the case that SIGMAR1 activation has a beneficial effect as a compensatory mechanism to chronic central nervous system (CNS) diseases.
Latest news
-
BMS builds case for cardiovascular drug mavacamten with new analysis
Hypertrophic cardiomyopathy (HCM) is a chronic and progressive disease which causes excessive contraction of the heart muscles and reduces the ability of the left ventricle to fill. ... Mavacamten represents Bristol Myers Squibb’s ongoing dedication to
-
Italy accelerates the path towards digital therapeutics implementation
involvement, such as those aimed at chronic diseases associated with dysfunctional lifestyles and behaviours in which the participatory role of the patient in the care pathway can be particularly relevant, as
-
Relics from the past
In chronic diseases, it is hard to find a therapy for which an enabling app is not being developed.
-
Novo Nordisk launches late-stage study in Alzheimer’s disease
As a company we aspire to address high unmet medical needs within serious chronic diseases, and we are therefore pleased to initiate phase 3 development of semaglutide within Alzheimer’s disease,”
-
Bayer's drop of the future
obviously, one of the world’s most important chronic diseases. ... And it hasn’t stopped there. It’s extended the same idea to hyperlipidaemia and hypertension, the two other big chronic conditions whose populations overlap.
BMS builds case for cardiovascular drug mavacamten with new analysis
Italy accelerates the path towards digital therapeutics implementation
Relics from the past
Novo Nordisk launches late-stage study in Alzheimer’s disease
Bayer's drop of the future
More from news
Approximately 2 fully matching, plus 183 partially matching documents found.
Latest Intelligence
-
Successful product commercialisation: what can we learn from the rare disease setting?
This trend is not surprising – in part driven by the pressures facing healthcare budgets through the rising incidence of chronic diseases, as well as the advent of cell and gene therapies ... For many therapies (from chronic diseases to paediatric rare
-
Why digital is the solution to the healthcare crisis
Innovation in the healthcare industry rapidly accelerated as a direct consequence of an ageing population, the rising prevalence of chronic diseases, infrastructure advancements, evolving care models, higher labour costs, staff shortages
-
Digital healthcare may revolutionise management of chronic diseases, but who is going to pay for it?
Much of this growth is being driven by the urgent need to innovate in chronic diseases such as cancer, diabetes, mental illness, heart disease and respiratory disease. ... Approximately half of all adults worldwide today are living with a chronic
-
The US celebrates five years of biosimilars on the market – a look to the past, present and future
chronic diseases such as rheumatoid arthritis. ... As these medicines become more commonplace, and as the US population continues to age and face rising rates of chronic disease, the associated costs will likely continue to rise.
-
Power to the patient: digital innovation supporting patients with chronic diseases
While these new and revamped assets are crucial in managing patient care, digital channels have long been utilised to directly engage and support those living with chronic diseases.
Successful product commercialisation: what can we learn from the rare disease setting?
Why digital is the solution to the healthcare crisis
Digital healthcare may revolutionise management of chronic diseases, but who is going to pay for it?
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Power to the patient: digital innovation supporting patients with chronic diseases
More from intelligence
Approximately 2 fully matching, plus 58 partially matching documents found.
Latest appointments
-
Kymab appoints its first chief medical officer
She has over 20 years of experience biomedical research and has focused on pathogenic mechanisms, underlying chronic inflammatory diseases and the interface between autoimmunity and cancer.
-
Dr Li Zhou joins TxCell as cell engineering VP
Dr Zhou will lead the team's discovery and engineering activities on Chimeric Antigen Receptor in Treg cells ( CAR-Treg) for immunotherapy of severe chronic autoimmune and inflammatory diseases and organ
-
Sanofi’s US pharma head joins Synta as CEO
She now leads an emerging US-based biopharma focused on the development of small molecule drugs to treat patients with severe medical conditions, including cancer and chronic inflammatory diseases.
-
Medgenics confirms appointment of Dr Marvin Garovoy
The company's Biopump uses a patient's own tissue to continuously produce and deliver their protein therapy and, potentially, has applications in a range of chronic diseases, including diabetes, multiple
Kymab appoints its first chief medical officer
Dr Li Zhou joins TxCell as cell engineering VP
Sanofi’s US pharma head joins Synta as CEO
More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.
Latest from PMHub
-
Nanobiotechnology, Artificial Intelligence, and Virtual Care
Venk Varadan, Co-founder &CEO at Nanowear, explores the use of cloth-based nanosensor technology, AI, and deep-learning-enabled diagnostics for remote monitoring of congestive heart failure, chronic diseases, and
-
#DemandDiversity: For International Women's Day, we ask... why do women often suffer from more side effects than men?
Further to this, the tests used to diagnose cardiac diseases function differently between men and women. ... However, once these trials are divided up into specific diseases the underrepresentation becomes clearer, especially in the fields of
-
Licensing Deal for NP213 Nail Fungus Treatment is Another Key Milestone for NovaBiotics
therapy for the treatment of airway infections associated with CF, ABPA and other acute and chronic fungal diseases of the respiratory tract.
-
October 2020: diversity and inclusion in clinical trials round-up
In the U.S., these chronic conditions disproportionately affect minority populations, meaning minorities entered the pandemic with health disparities that put them at a disadvantage. ... In the U.S., fewer healthcare providers have training, knowledge,
-
In the precision medicine era, the line between products and services is blurred
This has gained a lot of attention in recent years due to revolutionary breakthroughs in debilitating chronic diseases such as cancer.
#DemandDiversity: For International Women's Day, we ask... why do women often suffer from more side effects than men?
October 2020: diversity and inclusion in clinical trials round-up
More from PMHub
Approximately 5 fully matching, plus 30 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Events Executive
-
Depending on Experience
- Principal/ Senior/ Medical Writer – Global Med Ed and Comms Agen...
-
Highly competitive salary
- Project Director, Healthcare Marketing Agency patient focus Lond...
-
Highly competitive salary
- Digital Project Director, Healthcare Marketing Agency patient fo...
-
Highly competitive salary
- Senior Consultant, Pricing & Market Access Consultancy, circ...
-
circa £100K package
- Account Manager - Healthcare Consultancy
-
Salary depending on experience
-
Digital account director
-
Competitive
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- Mixing AZ and Pfizer COVID-19 vaccines increases antibody levels
- AZ publishes new real-world safety data for COVID-19 vaccine Vaxzevria
- The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
- CHMP rejects Kyowa Kirin’s Parkinson’s disease drug
- Google’s DeepMind opens ‘breakthrough’ protein database to the world
- Merck & Co’s sales bounce back in ‘ongoing recovery from COVID-19’
- Lilly and Kumquat Biosciences link up in $2bn-plus immuno-oncology deal
- Michael J. Fox Foundation and IBM reveal new AI model for Parkinson’s disease
- BMS’ Q2 results beat expectations with strong performance across core therapy areas
- Amanda Pritchard becomes NHS England’s first female chief executive
- Understanding the ‘real world’ starts and ends with the patient
No results were found
PMHub
Viseven
Viseven is a full cycle digital agency with 10 years expertise in developing content for the global pharmaceutical market delivering...
Latest intelligence
- Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
- The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
- Employee wellbeing in creative agencies: three tips to get you started
- Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...
- Managing unhelpful pressure in your creative agency: the human approach
- Paul Hutchings, founder of fox&cat, answers the questions: what does it mean to be human in 2021? Are we putting ourselves under too much pressure?...
